Voyager Therapeutics, Inc. · NASDAQ:VYGR

Voyager Therapeutics — Citi 2025 Biopharma Back to School Conference

12 slides from Voyager Therapeutics's conference presentation, Sep 2, 2025

  1. Slide 1: Leveraging Genetics to Treat Neurological Diseases

    Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025

  2. Slide 2: Forward-Looking Statements

    2 | Forward - Looking Statements This presentation contains forward - looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws . The use of words such as “anticipate,” “expect,” “believe,” “plan,” “

  3. Slide 3: Voyager (NASDAQ: VYGR) Investment Rationale

    3 | Voyager (NASDAQ: VYGR) Investment Rationale STRATEGY TO MITIGATE NEURO RISK NEURO PIPELINE TOP PEOPLE + PARTNERS 1 Based on our current operating plans, cash and cash equivalents and marketable securities as of June 30, 2025, along with amo unt s expected to be received as reimbursement for deve

  4. Slide 4: Voyager (NASDAQ: VYGR) Investment Rationale

    4 | Voyager (NASDAQ: VYGR) Investment Rationale STRATEGY TO MITIGATE NEURO RISK NEURO PIPELINE TOP PEOPLE + PARTNERS 1 Based on our current operating plans, cash and cash equivalents and marketable securities as of June 30, 2025, along with amo unt s expected to be received as reimbursement for deve

  5. Slide 5: Next-Generation TfR Shuttles Show Transformative Benefit for CNS Biotherapeutics

    5 | 1 st - Generation TfR Shuttles Show Transformative Benefit for CNS Biotherapeutics… Building on First - Generation Transferrin Receptor (TfR) Shuttles Each BBB transporter target offers unique properties: • Pharmacokinetics of delivery (e.g. TfR provides rapid uptake with fast clearance) • Biodi

  6. Slide 6: VYGR-NeuroShuttle: Next-Gen Approach to Neurotherapeutics

    6 | VYGR - NeuroShuttle : Next - Gen Approach to Neurotherapeutics TRACER AAV capsid discovery platform ALPL - VYGR - NeuroShuttle Receptor Y, Receptor 7, etc. Potential to deliver a diversity of therapeutic modalities: • Antibodies • Enzymes • Genome editors • ASOs • siRNAs • Peptides Voyager Neuro

  7. Slide 7: 1st-Gen TfR Shuttles Show Rapid Brain Uptake, Short Half-Life

    7 | 1 st - Gen TfR Shuttles Show Rapid Brain Uptake, Short Half - Life 1. Kariolis et al STM 2020. [Denali] 2. US20230174646A1 [Aliada] TfR Shuttle 1 TfR Shuttle 2 Time (days) 0 1 2 3 4 5 6 7 0.01 0.1 1 10 100 Plasma PK 50 mg/kg IV, hTfR KI mice Anti - BACE1 ATV35.21:BACE1 ATV35:BACE1 Serum PK Brain

  8. Slide 8: ALPL-VYGR-NeuroShuttle Demonstrates Sustained Brain Exposures

    8 | ALPL - VYGR - NeuroShuttle Demonstrates Sustained Brain Exposures Proof of concept murine data 1 show sustained CNS exposure for ALPL versus TfR shuttles 1. Voyager data on file. Brain PK Plasma PK • Increased antibody concentration in brain; modest impact on peripheral clearance • Brain uptake

  9. Slide 9: On-Target Risk of Anemia When Targeting TfR

    9 | On - Target Risk of Anemia When Targeting TfR 1. Klein et. al., Trontinemab ADPD 2025 as presented at Roche Virtual IR Event, April 2025. TfR engagement is known to impact circulating reticulocytes, causing a risk of anemia. Administration of trontinemab induced transient and mostly mild anemia

  10. Slide 10: Potential for ALPL-VYGR-NeuroShuttle Differentiation on Safety

    10 | Potential for ALPL - VYGR - NeuroShuttle Differentiation on Safety 1. Voyager data on file. 2 . Goettsch et al. Cardiovascular Research. 2022. 118:84 - 96. 3. Farman MR, et. al., The ALPL gene variant project: results of the f irst 100 reclassified variants. JBMR Plus. 2025 Mar 17;9(6):ziaf044.

  11. Slide 11: Market + Acquirers Appreciate Shuttle Opportunity and Value

    11 | Market + Acquirers Appreciate Shuttle Opportunity and Value Multiple potential opportunities for Voyager’s NeuroShuttle platform to create value: • Increase efficacy by increasing on - target delivery • Improve safety by reducing peripheral exposure • Lower COGS by reducing dose needed • Expand

  12. Slide 12: CNS Pipeline Focuses on Validated Targets with High Potential Value

    12 | CNS Pipeline Focuses on Validated Targets with High Potential Value Phase III Phase II Phase I IND - Enabling Research Mechanism / Indication Anti - tau Antibody (VY7523) / Alzheimer’s Disease Tau Silencing Gene Therapy (VY1706) (siRNA) / Alzheimer’s Disease APOE Gene Therapy / Alzheimer’s Dise

Voyager Therapeutics — Citi 2025 Biopharma Back to School Conference on 6ix